General Information of Drug (ID: DR0851)
Drug Name
BPI-2009
Synonyms
Conmana; Icotinib; Icotinib(Lcotinib); Lcotinib; QQLKULDARVNMAL-UHFFFAOYSA-N; SCHEMBL5843603; ZINC43207566; icotinib,BPI-2009H; 2468AH; 610798-31-7; 9G6U5L461Q; BCP21716; BDBM50391089; BPI 2009; BPI-2009; BPI-2009H; BPI2009; CHEMBL2087361; DTXSID20209952; EX-A306; GTPL7641; HMS3651F12; HY-15164A; MFCD22124501; N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine; N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine; UNII-9G6U5L461Q; s2922
Indication Lung cancer [ICD11: 2C25] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 391.4 Topological Polar Surface Area 74.7
Heavy Atom Count 29 Rotatable Bond Count 3
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
22024915
PubChem SID
37614496 ; 55538028 ; 85182161 ; 136920399 ; 139213683 ; 160707851 ; 160870172 ; 162009854 ; 162108694 ; 184815784 ; 198986148 ; 210275187 ; 210280827 ; 223365976 ; 223856036 ; 226087987 ; 231627548 ; 242060251 ; 247237456 ; 252472035
CAS Number
610798-31-7
TTD Drug ID
D06WRJ
Formula
C22H21N3O4
Canonical SMILES
C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4
InChI
1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
InChIKey
QQLKULDARVNMAL-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
BPI-2009 metabolite M11 DM002506 N. A. Oxidation - Hydroxylation 1 [2]
BPI-2009 metabolite M16 DM002503 N. A. Reduction - Reduction 1 [2]
BPI-2009 metabolite M4 DM002505 N. A. Oxidation - Oxidation 1 [2]
BPI-2009 metabolite M6 DM002507 N. A. Oxidation - Oxidation 1 [2]
BPI-2009 metabolite M7 DM002508 N. A. Oxidation - Oxidation 1 [2]
BPI-2009 metabolite M8 DM002509 N. A. Oxidation - Oxidation 1 [2]
BPI-2009 metabolite M15 DM002504
123639969
Oxidation - Dehydroxyethylation 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000419 BPI-2009 BPI-2009 metabolite M16 Reduction - Reduction Unclear [2]
MR000420 BPI-2009 BPI-2009 metabolite M4 Oxidation - Oxidation CYP3A4 ... [2]
MR000421 BPI-2009 BPI-2009 metabolite M11 Oxidation - Hydroxylation CYP2D6 [2]
MR000422 BPI-2009 BPI-2009 metabolite M6 Oxidation - Oxidation CYP2D6 [2]
MR000423 BPI-2009 BPI-2009 metabolite M7 Oxidation - Oxidation CYP2D6 [2]
MR000424 BPI-2009 BPI-2009 metabolite M8 Oxidation - Oxidation CYP2D6 [2]
MR000418 BPI-2009 metabolite M16 BPI-2009 metabolite M15 Oxidation - Dehydroxyethylation Unclear [2]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
References
1 ClinicalTrials.gov (NCT02486354) Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy.
2 Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.